Published in Nat Rev Cancer on January 10, 2013
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 2.46
TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature (2015) 2.33
Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity (2014) 2.27
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
The genomic landscape of retinoblastoma: a review. Clin Experiment Ophthalmol (2013) 1.81
STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun (2015) 1.63
Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure (2013) 1.63
The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52
Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer Cell (2016) 1.44
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res (2014) 1.34
Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev (2015) 1.31
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev (2014) 1.31
Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One (2013) 1.22
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem (2014) 1.21
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature (2016) 1.19
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl (2015) 1.17
Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets (2013) 1.14
Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One (2014) 1.10
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Aberrant regulation of FBW7 in cancer. Oncotarget (2014) 1.08
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ (2014) 1.07
Genomic profile analysis of diffuse-type gastric cancers. Genome Biol (2014) 1.07
The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. PLoS One (2015) 1.07
Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death. Sci Signal (2013) 1.06
Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. Elife (2014) 1.06
USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol (2014) 1.06
MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget (2014) 1.04
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol (2014) 1.04
Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget (2015) 1.01
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia (2015) 1.01
The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer (2016) 0.98
Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol (2016) 0.98
Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage. Cancer Cell (2014) 0.98
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat (2014) 0.97
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96
USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis (2013) 0.96
MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer. PLoS One (2014) 0.96
Caught in the cross fire: p53 in inflammation. Carcinogenesis (2014) 0.95
Chlamydia infection depends on a functional MDM2-p53 axis. Nat Commun (2014) 0.94
Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol (2014) 0.93
Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta (2014) 0.93
A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time. Cell Rep (2014) 0.93
MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle (2015) 0.92
The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target. Cell Cycle (2014) 0.92
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) (2014) 0.92
Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat (2014) 0.91
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov (2015) 0.91
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia (2013) 0.91
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer (2013) 0.91
Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing. Angew Chem Int Ed Engl (2015) 0.91
Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene (2014) 0.91
Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis. Int J Clin Exp Pathol (2013) 0.90
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun (2015) 0.90
Genome and network visualization facilitates the analyses of the effects of drugs and mutations on protein-protein and drug-protein networks. BMC Bioinformatics (2016) 0.90
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res (2014) 0.90
Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) (2013) 0.89
MDMX contains an autoinhibitory sequence element. Proc Natl Acad Sci U S A (2013) 0.89
Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ (2014) 0.89
RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis (2014) 0.88
MDMX exerts its oncogenic activity via suppression of retinoblastoma protein. Oncogene (2015) 0.88
miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ (2013) 0.88
Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov (2016) 0.88
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest (2015) 0.87
MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4. PLoS One (2015) 0.87
Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets (2014) 0.87
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. Oncotarget (2016) 0.86
Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum Mutat (2014) 0.86
Schedule-dependent interaction between anticancer treatments. Science (2016) 0.85
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int (2014) 0.85
Genomics of squamous cell lung cancer. Oncologist (2013) 0.85
The deubiquitinating enzyme USP24 is a regulator of the UV damage response. Cell Rep (2015) 0.85
Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget (2015) 0.85
Structure-based inhibition of protein-protein interactions. Eur J Med Chem (2014) 0.85
Cellular senescence and protein degradation: breaking down cancer. Cell Cycle (2014) 0.85
microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network. J Mol Cell Biol (2014) 0.84
Autoinhibition of MDMX by intramolecular p53 mimicry. Proc Natl Acad Sci U S A (2015) 0.84
USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition. Int J Mol Sci (2014) 0.84
A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast cancer in Zahedan, Southeast Iran. Iran Biomed J (2014) 0.83
Autoactivation of the MDM2 E3 ligase by intramolecular interaction. Mol Cell Biol (2014) 0.83
Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation. Genes Dev (2015) 0.83
F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress. Proc Natl Acad Sci U S A (2015) 0.83
Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. PLoS One (2014) 0.82
Specificity and disease in the ubiquitin system. Biochem Soc Trans (2016) 0.82
Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition. J Org Chem (2014) 0.82
PTEN plasticity: how the taming of a lethal gene can go too far. Trends Cell Biol (2013) 0.82
Role of p53 in the progression of gastric cancer. Oncotarget (2014) 0.82
Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis (2015) 0.81
Intravenous leiomyomatosis: an unusual intermediate between benign and malignant uterine smooth muscle tumors. Mod Pathol (2016) 0.81
SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis. BMC Neurol (2014) 0.81
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death Dis (2014) 0.81
SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells. Oncogenesis (2014) 0.81
Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction. Bioorg Med Chem (2013) 0.81
Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53. Structure (2015) 0.80
Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget (2015) 0.80
microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Oncotarget (2016) 0.79
Cancer: An essential passenger with p53. Nature (2015) 0.79
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer. Tumour Biol (2016) 0.79
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget (2016) 0.79
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
RING domain E3 ubiquitin ligases. Annu Rev Biochem (2009) 12.55
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell (2001) 11.39
Drug-target network. Nat Biotechnol (2007) 11.15
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol (2009) 5.41
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature (2006) 4.57
The microcosmos of cancer. Nature (2012) 4.50
Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J (1991) 4.33
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 3.35
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem (2006) 2.95
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88
Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. Nature (2012) 2.86
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol (2012) 2.67
p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell (2010) 2.65
A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med (2009) 2.65
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ (2010) 2.43
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol (2011) 2.39
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J (2005) 2.29
Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell (2009) 2.28
Will the ubiquitin system furnish as many drug targets as protein kinases? Cell (2010) 2.23
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J (2006) 2.21
MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem (2006) 2.20
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A (2006) 2.20
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem (2012) 2.01
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A (1998) 2.00
Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci U S A (2005) 1.97
Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem (2004) 1.95
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A (2009) 1.94
MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93
Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem (2006) 1.91
An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell (2010) 1.91
Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev (1997) 1.88
Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res (1997) 1.88
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J (2003) 1.85
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res (2007) 1.76
ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice. Cancer Cell (2012) 1.70
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem (2001) 1.66
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A (2011) 1.66
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
p53-based cancer therapy. Cold Spring Harb Perspect Biol (2010) 1.62
Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol (2011) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Stapled peptides for intracellular drug targets. Methods Enzymol (2012) 1.61
Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet (2012) 1.59
ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J (2009) 1.56
Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene (1995) 1.55
An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res (2010) 1.55
A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2009) 1.52
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 1.52
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest (2007) 1.49
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol (2005) 1.41
The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J (2010) 1.39
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene (2007) 1.35
MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol (2009) 1.31
Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. Mol Syst Biol (2010) 1.30
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A (2010) 1.29
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol (2012) 1.26
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature (2009) 8.70
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell (2002) 5.47
Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J (2004) 3.10
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem (2004) 2.46
The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A (2005) 2.40
Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell (2009) 2.28
Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem (2006) 1.91
Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res (2004) 1.90
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A (2010) 1.78
A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell (2012) 1.65
A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell (2006) 1.64
MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A (2007) 1.56
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer (2011) 1.54
Replication initiation patterns in the beta-globin loci of totipotent and differentiated murine cells: evidence for multiple initiation regions. Mol Cell Biol (2002) 1.32
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol (2013) 1.30
A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle (2005) 1.11
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle (2008) 1.11
Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci U S A (2013) 1.11
Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol (2006) 1.08
Reproducible doxycycline-inducible transgene expression at specific loci generated by Cre-recombinase mediated cassette exchange. Nucleic Acids Res (2005) 1.04
NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains. Antimicrob Agents Chemother (2002) 0.99
Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev (2011) 0.98
Bypassing Sir2 and O-acetyl-ADP-ribose in transcriptional silencing. Mol Cell (2008) 0.98
Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. J Biol Chem (2013) 0.91
AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol Cell Biol (2013) 0.90
RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res (2006) 0.88
p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene (2005) 0.87
Stem cells and the developing mammary gland. J Mammary Gland Biol Neoplasia (2013) 0.87
Use of a molecular genetic platform technology to produce human Wnt proteins reveals distinct local and distal signaling abilities. PLoS One (2013) 0.86
Explaining the biological activity of transactivation-deficient p53 variants. Nat Genet (2006) 0.85
Initiation of DNA replication at the human beta-globin 3' enhancer. Nucleic Acids Res (2005) 0.84
Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3γ inactivation of MDMX protein. J Biol Chem (2012) 0.84
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction. Mol Cancer Ther (2002) 0.81
Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo. Cell Cycle (2009) 0.79
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anticancer Drugs (2002) 0.78
The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation. J Pathol (2009) 0.76
What a difference a phosphate makes: life or death decided by a single amino acid in MDM2. Cancer Cell (2012) 0.75